已成功举办六届的BioCon China大会致力于搭建中国生物药企业、国内外监管机构以及全球领先生物制药公司的三方技术交流及合作平台国际年会。在过往的活动中，BioCon China已累积4000+人次来自全球生物制药行业内资深人士参与，320+家行业内领先的服务及产品供应商赞助参与，共计有450+位行业领军人物参与专家讲演分享与研讨。
Dr. Fan Xiaohu is a well-known expert in the field of Applied Immunology and gene therapy. In 2004, he made a major breakthrough in the basic research of the mechanism of children's blood group incompatibility with heart transplantation. In his original paper published by Nature Medicine, he clarified the mechanism of immune tolerance in the process of children's heart transplantation and demonstrated that infant patients need not consider A before transplantation. BO blood group matched. This achievement breaks the limitation of homogenous organ transplantation and greatly improves the chances of organ transplantation for children with diseases. Returning to China in 2014 and joining Kingsley Group, Kingsley subsidiary Nanjing Legendary Biology was founded in early 2015. Excellent R&D team was established and advanced CAR-T technology platform was independently developed. LCAR-B38M, the first product for the treatment of relapsed and refractory multiple myeloma, achieved international leading results. Since its use in clinical trials in 2016, 74 people have been treated, with a complete response rate of 75%. This product has won a strategic partnership agreement between Johnson & Johnson and Legend to develop the global market for this product. On March 8, 2018, LCAR-B38M products were awarded the first clinical trial approval of CAR-T cell drugs in China, which became an important milestone in the history of cell therapy drugs in China. On May 30, 2018, LCAR-B38M products were also approved by the US FDA for phase Ib/II clinical trials. In 2019, he was eligible for the EU EMA Priority Drug Review. At present, Legendary Biology has the world's largest cell drug research and development team, developed a large number of new CAR-T cancer treatment products and a number of innovative intellectual property platform technology.